Home » Author Archive
About: James A. Datin

Jim Datin is Executive Vice President and Managing Director of the Deal Team at Safeguard Scientifics, Inc. (NYSE: SFE), a provider of growth capital and operational support for entrepreneurial and innovative life sciences and technology companies. At Safeguard, Jim applies his more than 25 years of experience to drive Safeguard’s partnership opportunities for both the life sciences and technology groups, which focus on molecular and point-of-care diagnostics, medical devices, regenerative medicine, specialty pharmaceuticals and selected healthcare services; and Internet / New Media, Financial Services IT, Healthcare IT and selected business services, respectively.
Over the course of his career, Jim has completed more than 50 transactions including venture investments, buyouts, acquisitions, mergers, IPOs, licensing and partnership agreements. He has been a successful CEO, raised capital for entrepreneurs to grow companies, and has turned around troubled companies throughout the United States, Europe and Asia.
Prior to Safeguard, Jim was CEO of Touchpoint Solutions; Group President of Dendrite International; Group Director, Corporate Business Strategy and Planning at GlaxoSmithKline; CEO of Isuta Holdings Berhad; and Director, International Business at Baxter/Merck KGaA.
Jim is a former board member of Intralinks, where he chaired the audit committee and filed the company’s SEC Form S-1 for its initial public offering. The company was acquired by TA & Associates, a large private holding firm, for more than $430 million, representing a 6x return to investors.
Jim currently is a member of the board for Safeguard’s partner companies NovaSom and Putney. In addition, Jim is on the Executive Board for Celerant Consulting; the Life Science Investment Advisory Committee for Ben Franklin Technology Partners of Pennsylvania; the Advisory Board for Sanofi Aventis, the board for Hepatitis B Foundation; and is Vice Chairman of the board for the University City Science Center in Philadelphia. He is a NASDAQ accredited and certified board member.
We’ve talked about Enterprise 3.0 before—how the evolution of social media, big data, mobile technology, Internet of Things, and cloud computing are transforming the enterprise. But more and more of the conversations at the healthcare and life sciences...
This week, Safeguard Scientifics’ life sciences team is in San Francisco attending J.P. Morgan’s 30th Annual Healthcare Conference, one of the healthcare industry’s largest annual meetings. The team is also spending time at partneringONE’s...
In the rush of the holidays, you may have missed some recent news from Safeguard Scientifics’ life sciences partner company Alverix.
On December 20, 2011, Alverix announced that its partner Becton, Dickinson and Company (BD) has received 510(k)...
Recent news and predictions for venture capital have been anything but cheery. With a wobbly economy and uncertainty surrounding government reforms, investors are understandably cautious. Entrepreneur Magazine even goes so far as to ask whether venture...
Last week, I sat on a panel session at the IMPACT 2011 Venture Summit Mid-Atlantic conference held by the Greater Philadelphia Alliance for Capital and Technologies (PACT) and AlwaysOn. The summit is a premier venture conference in the Northeast,...
Safeguard Scientifics has a unique and consistent approach to putting capital to work in the life sciences sector. We target capital efficient diagnostic companies that we believe will have success with applications they submit to the FDA. In addition,...